NCT03187678 - Safety Study of the Switch From Oral Selexipag to Intravenous Selexipag in Subjects With Stable Pulmonary Arterial Hypertension | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 4, 2017

Primary Completion Date

May 29, 2018

Study Completion Date

May 29, 2018

Conditions

Pulmonary Arterial Hypertension

Interventions

DRUG

i.v. selexipag

Selexipag for intravenous administration, twice daily as an infusion over 87 min. The dose is individualized for each subject to correspond to his/her current oral dose of Uptravi®.

DRUG

oral selexipag (Uptravi)

Uptravi is used as an auxiliary medicinal product, as part of the PAH standard treatment and administered according to the local prescribing information

Trial Locations (8)

17475

Universitätsmedizin Greifswald, Klinik und Poliklinik für Innere Medizin B, Greifswald

20246

Universitätsklinikum Hamburg-Eppendorf, II. Medizinische Klinik und Poliklinik, Pneumologie, Hamburg

35392

Universitätsklinikum Giessen und Marburg GmbH, Medizinische Klinik und Poliklinik II, Pneumologie, Giessen

44195

Cleveland Clin Foundation - Dept of Pulm & Critical Care Med, Cleveland

92037

University of California San Diego Medical center - PULM VASCULAR DIV, La Jolla

02111-1552

TUFTS New England Medical Center - PULM / CRITICAL CARE & SLEEP, Boston

75390-8550

University of Texas Southwestern Medical Center, Dallas

04103

Universitätsklinikum Leipzig / Medizinischen Klinik und Poliklinik I, Pneumologie, Leipzig